DM Clinical Research is celebrating its 20th anniversary, a milestone that underscores its evolution from a vision of accessible, patient-centered research into one of the nation's leading integrated clinical research networks. Founded in 2006, the organization has grown to operate more than 35 research sites, providing access to a patient population of 1.97 million individuals across 32 therapeutic areas. Over the past two decades, DM Clinical has enrolled more than 35,000 patients in clinical trials, contributing to the development of safe, life-changing therapies for patients worldwide.
The significance of this anniversary extends beyond the company's internal achievements. DM Clinical's growth reflects a broader shift in clinical research toward greater patient access and diversity. By expanding its presence in underserved communities, the organization is helping to ensure that more patients have the opportunity to participate in trials, which is critical for developing therapies that are effective across different populations. This approach aligns with industry-wide efforts to improve representation in clinical research, a factor that regulators and sponsors increasingly emphasize.
"Reaching 20 years is incredibly meaningful to me. When I think about DM Clinical Research, I think first about the people, the employees who have poured their talent and heart into this organization, and the patients who have trusted us to be part of their healthcare journey," said Mohammad Millwala, Founder and CEO. "We've experienced so much growth and change over the past two decades, but what has never changed is our commitment to our patients and to doing meaningful work that makes a difference."
The company's partnerships with pharmaceutical, biotechnology, and contract research organizations have been central to its success. DM Clinical's integrated operating model combines local physician relationships and patient access with centralized infrastructure, delivering quality, speed, and consistent execution for sponsors. This model has earned recognition, including the SPRIA Award for vaccine enrollment, the Excellence in Patient Centricity Award, ViE's Best Clinical Trial Network Award, and the SCRS Site Spark Award. In 2025, Millwala received the SCRS Christine K. Pierre Site Impact Award, recognizing his leadership.
As DM Clinical enters its third decade, the company is focusing on expansion into new communities, broadening therapeutic expertise, and investing in innovative technologies to improve patient access. The 20th anniversary theme, "Champions of Clinical Research: 20 Years of Impact," reflects the teamwork and dedication that have driven its growth. With core values of Think Forward, Find a Way, Create Impact, Own It, and Win Together, the organization is poised to continue its mission of accelerating access to innovative therapies.
The implications of this anniversary are significant for the clinical research industry. DM Clinical's growth demonstrates the viability of integrated research networks in meeting the demand for diverse patient populations and efficient trial execution. As the industry faces increasing pressure to speed up drug development and improve inclusivity, DM Clinical's model offers a blueprint for how site networks can scale while maintaining patient-centricity. The company's commitment to underserved communities also highlights the ongoing need to address disparities in clinical trial participation, a key challenge for regulators and sponsors alike. By continuing to grow and innovate, DM Clinical is helping to shape the future of clinical research.
